82 results on '"Yoshikawa, T."'
Search Results
2. P-15 Histology classification highlights the difference in the effectiveness of S-1 over capecitabine when combined with cisplatin in patients with HER2-negative unresectable advanced or recurrent gastric cancer with measurable disease
3. 1417P Prediction of the peritoneal recurrence by macroscopic diagnosis of the serosal invasion in gastric cancer: Supplementary analysis of JCOG0110 study
4. 1397P Prognostic impact of infectious complications: Exploratory analysis of JCOG0501 phase III trial
5. 1399P Risk factors for body weight loss after gastrectomy for gastric cancer analysed from the JCOG1001 phase III trial
6. LBA74 Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study
7. PD-035 Efficacy and safety of second-line irinotecan based chemotherapy in early relapse patients with gastric cancer after adjuvant chemotherapy: exploratory subgroup analysis of TRICS trial
8. P-253 Multimodal analgesia combined with epidural anesthesia and intravenous administration of acetaminophen in perioperative management of esophagectomy using modified ERAS protocol
9. SENSITIVITY OF MICROCAVITY ARRAY SYSTEM FOR CIRCULATING TUMOR CELLS IN LUNG CANCER PATIENTS
10. 1439P Phase II study to evaluate feasibility and safety of oral nutritional supplementation with high density liquid diet after total gastrectomy for patients with gastric cancer
11. 1475P Negative impact of intraoperative blood loss on long-term outcome after curative gastrectomy for cT3/4a gastric cancer - Exploratory analysis of JCOG1001 study
12. P-81 phase I-II of the update of the EORTC quality of life gastric module QLQ-STO22
13. Subgroup analyses of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with 2 and 4 courses of cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) as neoadjuvant chemotherapy for locally advanced gastric cancer
14. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor: Exploratory analysis in the patients who were enrolled in JCOG0705/KGCA01 phase III trial (REGATTA) and could continue chemotherapy
15. Phase III KEYNOTE-585 study of chemotherapy (Chemo) + pembrolizumab (Pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (Pts) with gastric or gastroesophageal junction (G/GEJ) cancer
16. Diagnosis of invasion depth in resectable advanced gastric cancer for neoadjuvant chemotherapy: An exploratory analysis of JCOG1302A
17. End-to-end learning to predict survival in patients with gastric cancer using convolutional neural networks
18. The difference of risk factor for gastric cancer surgery between elderly and non-elderly patients
19. Volume reduction rate of the primary tumor of esophageal squamous cell carcinoma after neoadjuvant chemotherapy: Could this measurement be a surrogate end point for survival before surgery?
20. Can preoperative diagnosis select therapeutic target of neoadjuvant chemotherapy for gastric cancer?
21. A phase III study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data
22. A phase 3 study of chemotherapy + pembrolizumab vs chemotherapy + placebo as neoadjuvant/adjuvant treatment for patients with gastric or gastroesophageal junction (G/GEJ) cancer: KEYNOTE-585 - Trial in progress
23. Feasibility study of preoperative chemotherapy for esophageal cancer with naso-gastric ED tube for patients with difficulty of oral ingestion
24. Optimal cutoff of histological response by neoadjuvant chemotherapy for gastric cancer
25. Priority of lymphadenectomy for each station in elderly patients with middle to distal advanced gastric cancer
26. Clinical impact of postoperative surgical complications on the colorectal cancer survival and recurrence: Analyses of pooled individual patients’ data from three large phase III randomized trials
27. Impact of preoperative sarcopenia on overall survival in gastric cancer surgery
28. 794P - Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor: Exploratory analysis in the patients who were enrolled in JCOG0705/KGCA01 phase III trial (REGATTA) and could continue chemotherapy
29. 778P - Subgroup analyses of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with 2 and 4 courses of cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) as neoadjuvant chemotherapy for locally advanced gastric cancer
30. Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors
31. A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02)
32. Safety and efficacy of S-1 treatment in elderly patients with advanced or recurrent gastric cancer: A subgroup analysis from the phase III JFMC36-0701 trial
33. A randomized phase III trial comparing 4 courses and 8 courses of S-1 adjuvant chemotherapy for p-stage II gastric cancer: JCOG1104 (OPAS-1)
34. Biomarker analysis to predict the pathological response of locally advanced gastric cancer to neoadjuvant chemotherapy: an exploratory study of the randomized phase II COMPASS trial
35. Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with 2 and 4 courses of cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) as neoadjuvant chemotherapy for locally advanced gastric cancer
36. 784TiP - Phase III KEYNOTE-585 study of chemotherapy (Chemo) + pembrolizumab (Pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (Pts) with gastric or gastroesophageal junction (G/GEJ) cancer
37. 692P - The difference of risk factor for gastric cancer surgery between elderly and non-elderly patients
38. 657P - Can preoperative diagnosis select therapeutic target of neoadjuvant chemotherapy for gastric cancer?
39. 656P - Diagnosis of invasion depth in resectable advanced gastric cancer for neoadjuvant chemotherapy: An exploratory analysis of JCOG1302A
40. 639P - Volume reduction rate of the primary tumor of esophageal squamous cell carcinoma after neoadjuvant chemotherapy: Could this measurement be a surrogate end point for survival before surgery?
41. 617PD - A phase III study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data
42. 77P - End-to-end learning to predict survival in patients with gastric cancer using convolutional neural networks
43. P-091 Validation of Functional Assessment of Cancer Therapy-Gastric (FACT-Ga) and its sensitivity to ascites volume change: an analysis of two Japanese clinical trials
44. 198P Molecular biomarker study in randomized phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: XParTS IIb
45. P-096 - A phase 3 study of chemotherapy + pembrolizumab vs chemotherapy + placebo as neoadjuvant/adjuvant treatment for patients with gastric or gastroesophageal junction (G/GEJ) cancer: KEYNOTE-585 - Trial in progress
46. 225P - Feasibility study of preoperative chemotherapy for esophageal cancer with naso-gastric ED tube for patients with difficulty of oral ingestion
47. 214P - Priority of lymphadenectomy for each station in elderly patients with middle to distal advanced gastric cancer
48. 215P - Optimal cutoff of histological response by neoadjuvant chemotherapy for gastric cancer
49. 211P - Impact of preoperative sarcopenia on overall survival in gastric cancer surgery
50. 170P - Clinical impact of postoperative surgical complications on the colorectal cancer survival and recurrence: Analyses of pooled individual patients’ data from three large phase III randomized trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.